Henlius Usa Inc.

Henlius Usa Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Henlius USA Inc., located in Milpitas, CA, focuses on developing and delivering high-quality, innovative, and affordable medicine to patients worldwide to treat a range of chronic and life-threatening diseases with a focus in oncology and autoimmune diseases. Henlius USA Inc., is affiliated with Shanghai Henlius Biotech, a global biopharmaceutical company established in 2010. Henlius’ diverse pipeline of over 20 innovative monoclonal antibodies (mAb) includes 汉利康® (HLX01, rituximab injection, the first commercially launched biosimilar in China), 汉曲优® (HLX02, trastuzumab injection, Zercepac® in the EU, first Chinese mAb biosimilar approved in both EU and China), 2 products under NDA review, and over 20 clinical studies for 10 products and 8 combination therapies worldwide. Our goal at Henlius USA Inc., is to accelerate the discovery and development of innovative biologics (such as monoclonal and bispecific antibody) through technical and operational excellence and to build a leading immuno-oncology franchise with a diverse and distinguished product portfolio. We aim to be a globally trusted biotech company dedicated to bringing affordable, innovative treatment to patients with unmet medical needs worldwide. Henlius: http://www.henlius.com

Company Details

Employees
42
Founded
-
Address
430 N Mccarthy Blvd, Milpitas,california 95035,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Milpitas, California
Looking for a particular Henlius Usa Inc. employee's phone or email?

Henlius Usa Inc. Questions

News

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)-Media - 复宏汉霖

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)-Media 复宏汉霖

US FDA Accepts Biologics License Application (BLA) for HLX11, Biosimilar Candidate of Perjeta® (pertuzumab) - 复宏汉霖

US FDA Accepts Biologics License Application (BLA) for HLX11, Biosimilar Candidate of Perjeta® (pertuzumab) 复宏汉霖

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire

(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Business Wire

Henlius 2024 Second Scientific Advisory Board Meeting Held-Media - 复宏汉霖

Henlius 2024 Second Scientific Advisory Board Meeting Held-Media 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of nsNSCLC - 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of nsNSCLC 复宏汉霖

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Yahoo Finance

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe Yahoo Finance

Henlius and SVAX Forge Strategic Partnership in the MENAT Market-Media - 复宏汉霖

Henlius and SVAX Forge Strategic Partnership in the MENAT Market-Media 复宏汉霖

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC - 复宏汉霖

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - The AI Journal

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 The AI Journal

Henlius Trastuzumab Receives FDA Approval in the United States-Media - 复宏汉霖

Henlius Trastuzumab Receives FDA Approval in the United States-Media 复宏汉霖

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA - 复宏汉霖

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA 复宏汉霖

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 复宏汉霖

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 复宏汉霖

Henlius Passes Its Second EU GMP Inspection-Media - 复宏汉霖

Henlius Passes Its Second EU GMP Inspection-Media 复宏汉霖

Henlius to Showcase at BIO 2024-Media - 复宏汉霖

Henlius to Showcase at BIO 2024-Media 复宏汉霖

Henlius to Make Its Debut at the World ADC Asia 2024-Media - 复宏汉霖

Henlius to Make Its Debut at the World ADC Asia 2024-Media 复宏汉霖

Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43 - 复宏汉霖

Henlius Receives IND Approval from NMPA for a Phase 1b/2 Clinical Trial of Its Novel PD-L1-Targeting ADC HLX43 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC - 复宏汉霖

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX42-Media - 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX42-Media 复宏汉霖

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media - 复宏汉霖

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media 复宏汉霖

Henlius and Convalife Reach Global Strategic Cooperation on Neratinib-Media - 复宏汉霖

Henlius and Convalife Reach Global Strategic Cooperation on Neratinib-Media 复宏汉霖

Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43-Media - 复宏汉霖

Henlius Receives the FDA IND Approval for Its PD-L1-Targeting ADC Candidate HLX43-Media 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14-Media - 复宏汉霖

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14-Media 复宏汉霖

Henlius Trastuzumab Receives Approval in Canada-Media - 复宏汉霖

Henlius Trastuzumab Receives Approval in Canada-Media 复宏汉霖

Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15 - 复宏汉霖

Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15 复宏汉霖

Henlius Announces Successful Completion of Phase 1 PK Similarity Clinical Study of Denosumab HLX14 - 复宏汉霖

Henlius Announces Successful Completion of Phase 1 PK Similarity Clinical Study of Denosumab HLX14 复宏汉霖

Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC-Media - 复宏汉霖

Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC-Media 复宏汉霖

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America - 复宏汉霖

Henlius and Eurofarma Entered into a License Agreement for Henlius' 3 Products in Latin America 复宏汉霖

IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA-Media - 复宏汉霖

IND Application of Henlius’ Pembrolizumab Biosimilar Approved by NMPA-Media 复宏汉霖

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries - 复宏汉霖

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15-Media - 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15-Media 复宏汉霖

Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India - 复宏汉霖

Henlius Deepens Collaboration with Intas to bring Henlius’ Novel anti-PD-1 mAb Serplulimab to Europe and India 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43-Media - 复宏汉霖

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX43-Media 复宏汉霖

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media - 复宏汉霖

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media 复宏汉霖

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA-Media - 复宏汉霖

Henlius’ Novel Anti-TIGIT Fc Fusion Protein HLX53 IND Approved by NMPA-Media 复宏汉霖

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Yahoo Finance

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Yahoo Finance

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia - Business Wire

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia Business Wire

In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography - ACS Publications

In-Depth Characterization for Methionine Oxidization in Complementary Domain Region by Hydrophobic Interaction Chromatography ACS Publications

Making biologic medicines more accessible - Nature

Making biologic medicines more accessible Nature

In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry - ACS Publications

In-Depth Characterization of mAb Charge Variants by On-Line Multidimensional Liquid Chromatography-Mass Spectrometry ACS Publications

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies - Business Wire

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies Business Wire

Top Henlius Usa Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant